NASDAQ NMS - GLOBAL MARKET · RCKT
+0.76% · +$0.0200 · Vol Not reported
Pre-market · updated 07:00:10 ET
Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals Inc

Biotechnology
$2.65
Card
Relationship Map

Follow $RCKT

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $RCKT by email

Veridion Score

BETAMEDIUM CONF · 5 of 6 factors measuredMethodology
Sentiment absence reason unknown
RCKT
Rocket Pharmaceuticals Inc
Wed Sep 30 · last completed session · Pre-market · regular session opens 9:30 ET
Middle range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

54/ 100
Veridion Score
Middle range · MEDIUM confidence · 5 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5 of 6 factors measured · Wed Sep 30 · last completed session · Pre-market · regular session opens 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is RCKT moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading RCKT catalysts
About Rocket Pharmaceuticals Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2015
Employees
202
Country
US

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$2.63
Last session
Day high
$2.63
Last session
Day low
$2.63
Last session
Previous close
$2.63
52W high
$5.30
-50.00% from high
52W low
$2.59
2% of range
Market cap
$288.7M
EPS
$-0.4100
Beta
0.98
Shares out
109.8M
Avg volume
1.7M
VWAP
$2.63
Last session
Price history computed in-house
1W
-1.49%
1M
-28.95%
3M
-30.99%
1Y
-16.14%
YTD
-24.50%
SMA 50 $3.39 · below
SMA 200 $3.57 · below
52W position 2%

RCKT overview

Veridion Score
54
Registered · 2026-09-30
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around RCKT.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading RCKT Form 4 filings
Public disclosures

Congress activity in RCKT

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for RCKT in the cached public ledger.

Federal contracts

RCKT contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for RCKT in this window.
Lobbying spend

RCKT lobbying filings, year to date.

Registered lobbying filings matched to Rocket Pharmaceuticals Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for RCKT in this window.
Loading news for RCKT
Analyst ratings
Sovereign unlock shows live analyst consensus for RCKT.
Options
Sovereign unlock shows live options positioning for RCKT.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.